MetaCap

Larimar Therapeutics Inc. (LRMR)

NASDAQ: LRMRHealth CareBiotechnology: Pharmaceutical PreparationsUSD

3.14-0.08 (-2.48%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

LRMR stock chart

Technical analysis

Key statistics

All statistics
Market cap
$328.55M
EPS (TTM)
-$1.67
52-week range
1.92 – 6.42
Day range
2.96 – 3.22
Volume / Avg
1.71M / 1.38M
Beta
—

52-week range

$1.92$6.42

LRMR stock today

On Nov 20, LRMR ended the session at $3.14, shedding $0.08 (2.48%), versus the S&P 500's 3.70% decline. Shares are 51.1% below their 52-week high of $6.42, set on Feb 25, 2026 and 64.0% above the 52-week low of $1.92, in the middle of the past year's range. LRMR is down 17.6% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 11.8%.

Larimar Therapeutics has posted a net loss over the last twelve months (EPS of -$1.67), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About Larimar Therapeutics

Company profile

Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal disease. The company is based in Bala Cynwyd, Pennsylvania.

Industry
Biotechnology: Pharmaceutical Preparations
CEO
Dr. Carole S. Ben-Maimon M.D.
Headquarters
Bala Cynwyd, PA
Employees
71
IPO year
2014

Financial highlights

Full financials

Larimar Therapeutics reported a net loss of $165.7 million, compared with a loss of $80.6 million a year earlier.

Larimar Therapeutics annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue—————
Growth—————
Net income$-165.67M$-80.60M$-36.95M$-35.35M$-50.64M
EPS (diluted)—$-1.32$-0.84$-1.37$-2.95

Analyst forecast

Forecast

Consensus (11 analysts)

strong_buy

Avg. price target

$14.20+352.23%

  • Strong buy 2
  • Buy 9
  • Hold 0
  • Sell 0
  • Strong sell 0

Target range

Low $5.00High $26.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 16, 2026
EPS actual vs est.
$-0.29 vs $-0.35
Surprise
+17.14%

LRMR news

All LRMR news

Larimar Therapeutics peers

Health Care sector
LRMR peer companies
CompanyPrice% ChgMarket capCompare
INOInovio Pharmaceuticals Inc.1.76+2.92%$329.66Mvs LRMR
MPLTMapLight Therapeutics Inc.5.94-7.48%$330.12Mvs LRMR
AVIRAtea Pharmaceuticals Inc.3.96+0.76%$318.00Mvs LRMR
CTNMContineum Therapeutics Inc. Class A8.68-3.98%$340.83Mvs LRMR
PEPGPepGen Inc.3.78-3.82%$356.31Mvs LRMR
SPRYARS Pharmaceuticals Inc.2.96-11.90%$297.56Mvs LRMR
ASPEAspen Neuroscience Inc.12.42+0.24%$361.16Mvs LRMR
PBYIPuma Biotechnology Inc7.05-0.98%$364.47Mvs LRMR

Indexes, lists and sector

Larimar Therapeutics stock FAQ

What is Larimar Therapeutics's stock price today?

LRMR last traded at $3.14 as of Nov 20, 4:00 PM EST, down 2.48% on the day. Prices are delayed at least 15 minutes.

Who is Larimar Therapeutics's CEO?

Dr. Carole S. Ben-Maimon M.D. is the chief executive officer of Larimar Therapeutics Inc., which has about 71 employees.

What is the LRMR 52-week high?

The 52-week high for LRMR is $6.42 and the 52-week low is $1.92. The stock is currently 51.1% below its high.

Compare LRMR